GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF”/vilanterol “VI”.
Source: GSK news - Category: Pharmaceuticals Source Type: news